Anti-tumour drug more potent with light-directed delivery

Posted on Aug 21, 2009

PCI Biotech’s light-activated drug delivery system combines with tumour-targeting drugs to halt tumour growth at low doses Oslo, 19 August, 2009 – The effects of tumour-targeting drugs in mice are significantly enhanced by PCI Biotech’s light-activated delivery system, a new study shows. Researchers say this dual therapy approach could be employed to increase the effect […]

Light-directed drug delivery system slows growth of invasive tumours

Posted on Jul 14, 2009

PCI Biotech’s photochemical technology shows clinical potential in mouse models Oslo, 13 July, 2009 – PCI Biotech’s light-activated drug delivery system is able to significantly slow the growth of an invasive tumour in mice, according to a new study. Researchers say the study provides new evidence of the clinical potential of photochemical internalization (PCI) in […]

Allotted Share Options

Posted on Jun 28, 2009

In accordance with the Power of Attorney given at the general meeting on April 30, 2009, the Board of PCI Biotech ASA has allocated 234,000 share options to key personnel in the company. Oslo, Norway, June 22, 2009. The share options have a term of 1.25 to 3 years. Strike price for the share options […]